Coen Stacy Ann 4
4 · ImmunoGen, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
ImmunoGen, Inc.IMGN
Coen Stacy Ann
Chief Business Officer
Transactions
- Award
Common Stock
2023-12-29$16.01/sh+367$5,876→ 63,507 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-29−30,000→ 303,465 totalExercise: $5.32Exp: 2032-02-04→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2023-12-29$5.32/sh+30,000$159,600→ 63,140 total
Footnotes (3)
- [F1]These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2023 through December 31, 2023.
- [F2]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 3, 2023
- [F3]This option was granted on February 4, 2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.